login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMUNON INC (IMNN) Stock News
USA
-
Nasdaq
- NASDAQ:IMNN -
US15117N7012
-
Common Stock
3.64
USD
-0.05 (-1.36%)
Last: 11/21/2025, 8:00:02 PM
3.51
USD
-0.13 (-3.57%)
After Hours:
11/21/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMNN Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Chartmill
IMUNON INC (NASDAQ:IMNN) Stock Soars 199% on Clinical Progress and Earnings Beat
10 days ago - By: The Motley Fool
Imunon (IMNN) Q3 2025 Earnings Call Transcript
10 days ago - By: Imunon, Inc.
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
13 days ago - By: Imunon, Inc.
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
13 days ago - By: Imunon, Inc.
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
16 days ago - By: Imunon, Inc.
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
17 days ago - By: Imunon, Inc.
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
19 days ago - By: Imunon, Inc.
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
a month ago - By: Imunon, Inc.
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
a month ago - By: Imunon, Inc.
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
a month ago - By: Imunon, Inc.
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
a month ago - By: Imunon, Inc.
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
2 months ago - By: Imunon, Inc.
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
2 months ago - By: Imunon, Inc.
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
3 months ago - By: Imunon, Inc.
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: Imunon, Inc.
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4 months ago - By: Imunon, Inc.
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
4 months ago - By: Imunon, Inc.
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
4 months ago - By: Benzinga
Insights into Imunon's Upcoming Earnings
4 months ago - By: Stocktwits
- Mentions:
VXF
Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued
4 months ago - By: Imunon, Inc.
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
4 months ago - By: Imunon, Inc.
IMUNON Announces Stock Dividend Boosting Shareholder Value
4 months ago - By: Imunon, Inc.
IMUNON Announces Reverse Stock Split
4 months ago - By: Imunon, Inc.
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
5 months ago - By: Imunon, Inc.
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
5 months ago - By: Imunon, Inc.
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
5 months ago - By: Virtual Investor Conferences
- Mentions:
NIKA
TIVC
ADIA
STSS
...
Life Sciences Investor Forum: Now Available for Online Viewing
Please enable JavaScript to continue using this application.